FDA approves new Augtyro indication for NTRK-positive tumors

 Bristol Myers Squibb (NYSE: NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Augtyro™ (repotrectinib) as a treatment for certain patients with solid tumors. This new indication applies to adult and pediatric patients aged 12 and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic, or where surgical resection would result in severe morbidity, and who have progressed following treatment or have no satisfactory alternative therapy.